Abbott Sustainability Profile
Abbott Laboratories, commonly known as Abbott, is a leading global healthcare company headquartered in the United States. Founded in 1888, Abbott has established a strong presence in various operational regions, including North America, Europe, and Asia. The company operates primarily in the medical devices, diagnostics, nutrition, and pharmaceuticals sectors. Abbott is renowned for its innovative products, such as the FreeStyle Libre glucose monitoring system and Similac infant formula, which set industry standards for quality and effectiveness. With a commitment to advancing health and well-being, Abbott has achieved significant milestones, including the rapid development of COVID-19 testing solutions. As a market leader, Abbott consistently ranks among the top healthcare companies worldwide, recognised for its dedication to research and development, and its ability to deliver cutting-edge solutions that improve patient outcomes.
DitchCarbon Score
How does Abbott's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abbott's score of 67 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Abbott's reported carbon emissions
In 2024, Abbott reported total carbon emissions of approximately 10.9 billion kg CO2e, comprising 502 million kg CO2e from Scope 1, 393 million kg CO2e from Scope 2, and about 9.97 billion kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its absolute Scope 1 and 2 emissions by 30% from a 2018 baseline by 2030, aligning with the Science Based Targets initiative (SBTi) objectives. Additionally, Abbott aims to achieve near-zero emissions for both Scope 1 and Scope 2 by 2025. Abbott's commitment to sustainability includes a significant reduction in carbon emissions, with a goal of 50% reduction in overall emissions by 2030, as part of its 10-year environmental strategy initiated in 2020. The company also emphasizes the importance of engaging its suppliers, with a target that 82% of its suppliers by emissions will have science-based targets by 2026. The emissions data and reduction targets are sourced from Abbott Laboratories, reflecting the company's commitment to addressing climate change and reducing its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 578,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 691,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | - | - | - | - | - | 0,000,000,000 |
How Carbon Intensive is Abbott's Industry?
How Carbon Intensive is Abbott's Location?
Abbott's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 71% of Scope 3 emissions.
Top Scope 3 Categories
Abbott's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Abbott has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
GlaxoSmithKline Pharmaceuticals Limited
Frequently Asked Questions
Common questions about Abbott's sustainability data and climate commitments